Saturday 17 October 2026
Export CVRX’s income statement to Excel — free account
CVRx, Inc.
CVRX Healthcare Medical Devices
CVRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $56.7 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 7.02%, free cash flow fell 11.2% and total debt rose 18.6%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
1.30
0.09
−6.47%
Follow CVRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.77 | 3.27 | 4.22 | 2.23 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(21.75) | (18.98) | (20.50) | (15.44) | |
P/B ratio |
4.39 | 4.71 | 8.57 | 6.83 | |
Price to Tangible BV |
4.39 | 4.71 | 8.57 | 6.83 | |
EV/Sales |
3.20 | 2.87 | 4.04 | 2.18 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.65) | (4.04) | (6.04) | (3.30) | |
EV/FCF |
(4.59) | (3.98) | (5.95) | (3.25) | |
Quick Ratio |
8.32 | 6.49 | 8.58 | 6.65 | |
Current Ratio |
9.62 | 7.63 | 10.20 | 8.04 | |
Net Debt/EBITDA |
2.97 | 2.39 | 1.16 | 0.47 | |
Debt/Assets |
44.42% | 47.25% | 58.65% | 63.47% | |
Debt/Equity |
1.03 | 1.26 | 2.01 | 2.94 | |
Asset Turnover |
0.47 | 0.48 | 0.52 | 0.58 | |
Operating CF/Net income |
0.75 | 0.82 | 0.93 | 0.63 | |
Capex/Depreciation |
(1.16) | (0.28) | (0.42) | (0.38) | |
Interest Coverage |
(8.29) | (7.89) | (7.84) | (8.25) | |
Research and Development Expense of Revenue |
21.42% | 18.72% | 20.88% | 19.93% | |
Selling, General and Administrative Expense of Revenue |
148.91% | 137.35% | 148.68% | 150.38% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
19.66% | 17.43% | 19.74% | 23.34% | |
Graham Net Nets |
0.21 | 0.20 | 0.10 | 0.13 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(25.03%) | (28.87%) | (21.35%) | (38.52%) | |
Free Cash Flow Yield |
(18.46%) | (22.00%) | (16.11%) | (30.12%) | |
Revenue per Share |
0.56 | 0.61 | 0.56 | 0.59 | |
Operating CF per Share |
(0.37) | (0.37) | (0.46) | (0.33) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.38) | (0.38) | (0.47) | (0.34) | |
Cash per Share |
3.25 | 2.90 | 2.74 | 2.44 | |
Shareholders Equity per Share |
1.84 | 1.51 | 1.10 | 0.75 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.84 | 1.51 | 1.10 | 0.75 | |
Free Cash Flow |
(10.00) | (9.83) | (12.29) | (8.94) | |
Working Capital |
96.67 | 88.33 | 87.26 | 78.36 | |
Capital Expenditures |
(0.29) | (0.07) | (0.12) | (0.11) | |
Net Current Asset Value |
44.62 | 36.18 | 26.13 | 17.16 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
8.62 | 9.97 | 9.06 | 8.28 | |
Average Payables |
3.45 | 3.21 | 2.87 | 3.45 | |
Average Inventory |
11.64 | 12.16 | 12.04 | 12.37 | |
Average Assets |
119.50 | 119.10 | 114.66 | 105.92 | |
Average Common Equity |
56.62 | 55.19 | 49.23 | 38.94 |
Columns are period end dates